Evidence map›Paper›PMID 21543561›Full record

ArticleJournal of clinical microbiology2011

Identification of Toxoplasma gondii SUB1 antigen as a marker for acute infection by use of an innovative evaluation method.

A Hruzik, A R Asif, U Gross

Abstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Identification of novel biomarkers for anti-Frontiers in microbiology · 2024
    Article
  2. Mining the Proteome ofAnimals : an open access journal from MDPI · 2022
    Review
  3. Identification of Oocyst-DrivenMicroorganisms · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

A HruzikInstitute for Medical Microbiology, University Medical Center National Consulting Laboratory for Toxoplasmosis, Kreuzbergring 57, D-37075 Goettingen, Germany.
A R Asif
U Gross
Robert Koch Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By the separation of Toxoplasma lysate using two-dimensional gel electrophoresis and its analysis with human serum samples and mass spectrometry, the subtilisin-like protein (SUB1) was identified to be a potential marker for acute toxoplasmosis. Following expression of the C-terminal domain of SUB1 in Escherichia coli, it was tested in a line blot assay using a total of 80 human serum samples. Two computer programs based on different evaluation strategies were used for judgment of the line blot results: (i) a time-dependent method with a predefined cutoff value and (ii) a fixed-time-point method with a calculated cutoff. Thereby, SUB1 was proven to be rather reactive with specific immunoglobulin A (IgA), IgM, and IgG of patients with an acute infection. This finding makes this antigen an attractive candidate for improving diagnosis of toxoplasmosis and demonstrates that not only the selection of respective antigens but also the evaluation method chosen are important for the evaluation of new diagnostic markers.

Indexed as

Antigens, ProtozoanProtozoan ProteinsSubtilisinsAntibodies, ProtozoanBiomarkersClinical Laboratory TechniquesElectrophoresis, Gel, Two-DimensionalHumansImmunoassayImmunoglobulin AImmunoglobulin GImmunoglobulin MMass SpectrometryParasitologyProteomeSensitivity and SpecificityAntibodies, ProtozoanAntigens, ProtozoanBiomarkersImmunoglobulin AImmunoglobulin GImmunoglobulin MProteomeProtozoan ProteinsSUB1 protein, Toxoplasma gondiiSubtilisins

Identifiers

PMID21543561
PMCPMC3147871
OpenAlexW2098178345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.